1. Home
  2. TMDE vs NEUP Comparison

TMDE vs NEUP Comparison

Compare TMDE & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TMDE

TMD Energy Limited Ordinary Shares

HOLD

Current Price

$1.24

Market Cap

21.7M

Sector

Energy

ML Signal

HOLD

NEUP

Neuphoria Therapeutics Inc.

HOLD

Current Price

$4.66

Market Cap

23.8M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
TMDE
NEUP
Founded
2016
1996
Country
Malaysia
United States
Employees
N/A
8
Industry
Oil Refining/Marketing
Sector
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
21.7M
23.8M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
TMDE
NEUP
Price
$1.24
$4.66
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$21.00
AVG Volume (30 Days)
2.9M
49.5K
Earning Date
05-13-2026
05-23-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.41
$3.65
52 Week High
$4.77
$21.31

Technical Indicators

Market Signals
Indicator
TMDE
NEUP
Relative Strength Index (RSI) 45.80 55.07
Support Level $0.64 $3.91
Resistance Level $1.37 $5.06
Average True Range (ATR) 0.24 0.26
MACD -0.03 0.03
Stochastic Oscillator 14.75 84.04

Price Performance

Historical Comparison
TMDE
NEUP

About TMDE TMD Energy Limited Ordinary Shares

TMD Energy Ltd is engaged in marine fuel bunkering services specializing in the supply and marketing of marine gas oil and marine fuel oil (including high sulfur fuel oil, low sulfur fuel oil and very low sulfur fuel oil), to ships and vessels at sea. It is also involved in the provision of ship management services for in-house and external vessels, as well as vessel chartering. It is currently operating with a fleet of nearly 15 bunkering vessels ranging from 540 dwt to 7,820 dwt, of which nearly nine (9) are double bottom and double hull vessels with an average cargo-carrying capacity of approximately 4,200 dwt each.

About NEUP Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.

Share on Social Networks: